E-Prescription System Funding Transparency Recommended In Pfizer Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Electronic prescribing systems should be designed to prevent the promotion of pharmaceuticals for non-clinical reasons, such as the benefit to third-party entities that may fund the system, a RAND expert panel suggests in a report commissioned by Pfizer.